May 24, 2021 / 12:30PM GMT
Operator
Good morning, and welcome to NGM Bio's conference call. (Operator Instructions) As a reminder, today's call is being recorded.
I would now like to turn the call over to Alex Schwartz, Head of Investor Relations. You may begin.
Alexander Schwartz -
Thank you, Catherine, and good morning, everyone. Thank you for joining us to discuss the top line data from ALPINE 2/3, our Phase IIb study evaluating treatment of aldafermin in patients with NASH and stage 2 or 3 liver fibrosis over 24 weeks. During this call, we will refer to our press release issued this morning as well as accompanying slides, which are available in the Investor and Media section of our corporate website at ngmbio.com.
On the call with me today with prepared remarks are David Woodhouse, Chief Executive Officer; and Hsiao Lieu, Chief Medical Officer; as well as Siobhan Nolan Mangini, Chief Financial Officer, who will join us for the question-and-answer period.
We remind you that during this call, we will be making forward-looking statements, including those detailed on Slide 2
NGM Biopharmaceuticals Inc Phase 2b ALPINE 2/3 Study Results Call Transcript
May 24, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers